Sarepta Therapeutics (SRPT) Inventory Average (2016 - 2026)

Sarepta Therapeutics' Inventory Average history runs 11 years deep, the most recent figure standing at $957.9 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 13.27% year-over-year to $957.9 million in Q1 2026; TTM through Mar 2026 was $957.9 million, a 13.27% increase from a year earlier, with the FY2025 full-year figure at $832.4 million, up 55.17% from the prior year.
• Inventory Average retreated to $957.9 million in Q1 2026 per SRPT's latest filing, from $996.0 million in the prior quarter.
• Across five years, Inventory Average topped out at $1.0 billion in Q3 2025 and bottomed at $192.6 million in Q1 2022.
• The 5-year median for Inventory Average is $348.2 million (2024), against an average of $501.5 million.
• Across the five-year window, Inventory Average dropped 22.96% in 2022 and jumped 142.88% in 2025, its largest moves.
• Year by year, Inventory Average stood at $212.6 million in 2022, then jumped by 33.33% to $283.4 million in 2023, then soared by 132.13% to $657.9 million in 2024, then soared by 51.37% to $996.0 million in 2025, then decreased by 3.82% to $957.9 million in 2026.
• Per Business Quant, the three latest SRPT Inventory Average figures stand at $957.9 million (Q1 2026), $996.0 million (Q4 2025), and $1.0 billion (Q3 2025).